Senseonics (NYSE:SENS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a report published on Monday. The firm issued a sell rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

NYSE SENS opened at $0.31 on Monday. Senseonics has a 1 year low of $0.28 and a 1 year high of $0.75. The stock has a market capitalization of $184.61 million, a P/E ratio of -2.39 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.38.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after acquiring an additional 179,103 shares in the last quarter. Symmetry Partners LLC bought a new position in shares of Senseonics during the 3rd quarter worth approximately $164,000. Cubist Systematic Strategies LLC increased its position in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.